We are live on ! Find out more
CLDI icon

Calidi Biotherapeutics
CLDI

28 hedge funds and large institutions have $479K invested in Calidi Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

21% more ownership

Funds ownership: 6.25% → 27.26% (+21%)

4% more funds holding

Funds holding: 27 → 28 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less capital invested

Capital invested by funds: $525K → $479K (-$45.9K)

Holders
28
Holders Change
+1
Holders Change %
+3.7%
% of All Funds
0.34%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
7
Increased
7
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$660K
2
SM
Sabby Management
Florida
+$327K
3
WAM
Warberg Asset Management
Illinois
+$188K
4
VF
Virtu Financial
New York
+$41K
5
AAP
Arax Advisory Partners
Colorado
+$28.1K

Top Sellers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
-$173K
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$16.3K
3
UBS Group
UBS Group
Switzerland
-$8.79K
4
TRCT
Tower Research Capital (TRC)
New York
-$1.03K
5
BC
Barrett & Company
Rhode Island
-$342
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$210K +$660K +879,000 New
SM
2
Sabby Management
Florida
$104K +$327K +434,903 New
WAM
3
Warberg Asset Management
Illinois
$59.5K +$188K +250,000 New
HighTower Advisors
4
HighTower Advisors
Illinois
$19.9K – – –
VF
5
Virtu Financial
New York
$18K +$41K +54,526 +257%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$15K +$15.8K +21,090 +50%
RCI
7
RS Crum Inc
California
$9.61K +$15K +20,000 +99%
AAP
8
Arax Advisory Partners
Colorado
$8.92K +$28.1K +37,345 New
Jane Street
9
Jane Street
New York
$8.31K +$17.5K +23,311 +203%
VCM
10
Vanguard Capital Management
Pennsylvania
$6.1K +$19.2K +25,509 New
BAM
11
Belpointe Asset Management
Nevada
$4.76K -$38 -50 -0.3%
Northern Trust
12
Northern Trust
Illinois
$4.24K – – –
FFA
13
Farther Finance Advisors
California
$2.43K – – –
Morgan Stanley
14
Morgan Stanley
New York
$2.26K +$6.01K +8,000 +545%
VFT
15
Vanguard Fiduciary Trust
Pennsylvania
$2.2K +$6.92K +9,219 New
HF
16
HRT Financial
New York
$2K +$7.61K +10,133 New
Osaic Holdings
17
Osaic Holdings
Arizona
$503 – – –
TRCT
18
Tower Research Capital (TRC)
New York
$333 -$1.03K -1,378 -50%
AMH
19
Apollo Management Holdings
New York
$249 – – –
FC
20
Finepoint Capital
Massachusetts
$249 – – –
HCM
21
Highbridge Capital Management
New York
$248 – – –
Fidelity Investments
22
Fidelity Investments
Massachusetts
$61 -$16.3K -21,758 -99%
SS
23
SBI Securities
Japan
$27 +$52 +69 +150%
TCM
24
Tradewinds Capital Management
Washington
$25 – – –
RFA
25
Reyes Financial Architecture
California
$24 – – –
1
2

CLDI Hedge Fund Activity: Q1 2026 in Review

28 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q1 2026, worth a combined $479K — down 8.7% from $525K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CLDI positions and 5 closed out — a net gain of 2 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $660K. The largest seller was DRW Securities, exiting entirely with an estimated $173K sold.

  • 28 institutional investors held Calidi Biotherapeutics (CLDI) as of Q1 2026, up from 27 in Q4 2025.
  • Funds reported $479K of Calidi Biotherapeutics stock for Q1 2026, down 8.7% quarter-over-quarter.
  • 7 funds opened new Calidi Biotherapeutics positions in Q1 2026 and 5 closed out, a net change of +2 holders.
  • The largest Calidi Biotherapeutics buyer in Q1 2026 was Armistice Capital, an estimated $660K added.
  • The largest Calidi Biotherapeutics seller in Q1 2026 was DRW Securities, an estimated $173K sold.

Based on aggregated 13F filings for Q1 2026.